Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications

Javier Donate-Correa, Carla M. Ferri, Fátima Sánchez-Quintana, Atteneri Pérez-Castro, Ainhoa González-Luis, Ernesto Martín-Núñez, Carmen Mora-Fernández and Juan F. Navarro-González

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and a main contributing factor for cardiovascular morbidity and mortality in patients with diabetes mellitus. Strategies employed to delay the progression of this pathology focus on the control of traditional risk factors, such as hyperglycemia, and elevated blood pressure. Although the intimate mechanisms involved in the onset and progression of DKD remain incompletely understood, inflammation is currently recognized as one of the main underlying processes. Untangling the mechanisms involved in the appearing of a harmful inflammatory response in the diabetic patient is crucial for the development of new therapeutic strategies. In this review, we focus on the inflammation-related pathogenic mechanisms involved in DKD and in the therapeutic utility of new anti-inflammatory strategies.

Keywords: diabetic kidney disease, inflammation, inflammatory cytokines, SGLT2i, GLP-1RA, DPP-4i, pentoxifylline

INTRODUCTION

Diabetic kidney disease (DKD) is a frequent complication in patients with diabetes mellitus (DM) and constitutes the first cause of kidney disease and an important risk factor for cardiovascular disease in this population (1, 2). DKD is characterized by a plethora of alterations including hemodynamic and metabolic abnormalities, the activation of the renin–angiotensin system (RAS), oxidative stress, and fibrosis, which together trigger the elevation of systemic and intraglomerular pressure, and the appearing of various symptoms related to the development of kidney failure: glomerular hypertrophy, proteinuria, and decreased glomerular filtration (3). Until recently, kidney involvement was only considered as the result of alterations in hemodynamic and metabolic factors; however, recent advances show that DKD is a complex and multifactorial process.

An increasing number of clinical and experimental studies have pointed out that inflammation contributes to the development and progression of DKD (4). Therefore, inflammatory mediators may represent new targets for the development of therapeutic strategies for the treatment of this complication. In this review, we discuss the pathophysiologic and therapeutic implications of the inflammatory cytokines in DKD.
INFLAMMATORY CYTOKINES IN THE SETTING OF DKD

Diverse inflammatory parameters are predictors of the evolution of the DM (5, 6), including the initiation and progression of DKD (4). These include inflammatory cytokines which, in addition to their role as regulators of the immune response, also exert important actions as cardinal effectors of injury. The increase in the levels of these molecules in the diabetic patient leads to microvascular complications such as the development of nephropathy (7–9). Proinflammatory cytokines, both circulating and those synthesized and secreted by inflammatory cells in the renal tissue, are elevated in patients with DKD (10–13), being directly associated with urinary albumin excretion (UAE) levels and with clinical markers of glomerular and tubulointerstitial damage (14, 15) (Figure 1).

Urinary levels of interleukin (IL) 6 and IL8 are significantly increased in microalbuminuric diabetic patients with early progressive renal function decline when compared to microalbuminuric or normoalbuminuric subjects with stable renal function (16). IL6 levels are upregulated in patients with DM and nephropathy (17); in the same way, the expression of mRNA encoding IL6 is also increased in renal cells (glomerular, epithelial, mesangial), as well as in kidney infiltrating-cells in patients with DKD compared to diabetic patients without kidney disease (17). Importantly, the expression levels of IL6 mRNA are positively related with the severity of mesangial expansion, a characteristic histological manifestation of DKD.

IL18 is another potent pro-inflammatory cytokine that exhibits elevated serum and urinary levels in patients with DKD, showing significant and direct correlations with UAE levels and with the evolution of albuminuria (7, 18, 19). Additionally, serum levels of IL18 are associated with urinary β-2 microglobulin, a marker of tubular dysfunction (18). IL18 is capable of regulating the synthesis of pro-inflammatory molecules such as IL1 and tumor necrosis factor (TNF) α, and interferon (IFN) γ (20), in turn increasing chemokine receptors in mesangial cells (21). Furthermore, IL8 increases the expression of intercellular adhesion molecule 1 (ICAM-1) (22) and promotes endothelial cell apoptosis (23). In addition to infiltrating cells, kidney tubular cells of patients with DKD also express increased levels of IL18 (24), which is related to the activation of the mitogen-activated protein kinase (MAPK) pathways by transforming growth factor (TGF) β (25).

Both serum and urinary levels of the cytokine TNFα are also elevated in patients with DKD (26). Moreover, this increase parallels the progression of renal damage, which may indicate a relationship with the development and progression of renal impairment in the diabetic patient (7, 9, 27). In these subjects, the rise in TNFα has been related with renal damage mediated by cytotoxic effects (26). Similar to IL18, TNFα is also expressed in endothelial, epithelial, mesangial, and tubular renal cells (28, 29). Importantly, animal models of diabetes present increased levels of TNFα in kidney glomeruli and tubules (9, 30–33) being directly and independently related with UAE (32).

Animal models of DKD show upregulation of IL1 expression in many types of kidney cells (31, 34). This increment has been related with the expression of ICAM-1, the vascular cell adhesion molecule-1 (VCAM-1), and the endothelial-leukocyte adhesion molecule-1 (ELAM-1) (35, 36), molecules involved in chemotaxis and adhesion processes. Rat kidney mesangial cells are stimulated to produce prostaglandin E2 after being incubated with recombinant IL1 (37) in response to Ang II (38), which is related to the appearing of abnormalities in intraglomerular hemodynamics. Finally, IL1 has been also related with the production of hyaluronin in the proximal tube (39), which is related with the development of experimental hypercellularity (40).

The cytokine IL17A is a member of the IL17 family mainly produced by activated T helper (Th) lymphocytes Th17 and, at lesser extent, by macrophages, neutrophils, natural killer, dendritic, and mast cells. Circulating IL17A levels have been related with the severity of kidney disease, showing a progressive decrease from subjects with normal glucose tolerance to subjects with DM with and without DN (41, 42). In opposite with these findings, other authors have found increased IL17A plasma values in patients with DN compared to healthy controls (43). These paradoxical findings might be by the fact that the modulatory effects of IL17A on inflammation may be dependent on disease context, tissue, isoform, and receptor-ligand interactions (44).

PATHOPHYSIOLOGIC IMPLICATIONS

The pathophysiologic implications of the inflammation on DKD occur at various levels. In a first level, inflammatory cytokines, acting in a paracrine or autocrine form, trigger the epithelial-to-mesenchymal transition process in the kidney (45), causing extracellular matrix accumulation. Secondly, the up-regulation of chemoattractant cytokines and adhesion molecules stimulates the attraction of circulating cells and facilitate their infiltration into the renal tissue. Finally, these cells amplify the inflammatory reaction, generating more cytokines and other mediators that contribute to the development and progression of renal injury (Figure 1).

The first clue suggesting the existence of a pathogenic role of these molecules in the DKD was obtained in vitro by incubating macrophages in a glomerular basement membrane derived from diabetic rats; these macrophages presented increased production of IL1 and TNFα when compared to macrophages incubated with membranes from normal animals (8).

The interleukins IL1, IL6, and IL8, have been clearly related to renal disorders in DKD (31, 34). IL1 has been linked with the proliferation of mesangial cells and matrix synthesis, thereby altering the renal architecture, with increased permeability of vascular endothelial cells, and with intraglomerular hemodynamic abnormalities secondary to alterations in prostaglandin production (37, 46). In DKD patients, the expression of mRNA molecules encoding IL6 is positively related with the severity of mesangial expansion (17). The up-regulation of this cytokine have been also related to another functional and structural abnormalities related to
Inflammatory pathophysiology in diabetic kidney disease. The diabetic milieu drives to the development of inflammation that includes the activation of immune cells and the upregulation of pro-inflammatory cytokines. Activated immune cells migrates and infiltrates the renal tissue locally producing more inflammatory mediators and chemokines that recruit more immune cells into the kidney. Moreover, activated resident renal cells can also produce additional proinflammatory mediators, contributing to sustained inflammation, and the induction of kidney damage. Created with BioRender.com.

Table 1: Therapeutic strategies in the DKD with potential anti-inflammatory properties.

| Drug                      | Primary target                                      | Main outcomes in DKD                                                                 | Anti-inflammatory effects                                                                 | References |
|---------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------|
| RAS blockers              | Inhibition of ACE or blockade of angiotensin II receptor. | Reduce proteinuria and the progression of nephropathy.                               | Inhibition of NF-κB, MCP1 gene expression, and macrophage infiltration.                   | (68, 69)   |
| SGLT2 inhibitors          | Blockade of glucose reabsorption by SGLT2 at the proximal tubule. | Improved glycemic control. Slower progression of kidney disease and lower rates of clinically relevant renal events. | Reduction of inflammation by targeting the IL18 and reduction of hsCRP, TNFα, IL6, and IFNγ. | (70–90)    |
| DPP4 inhibitors and GLP-1 receptor agonists | Stimulation of glucose-dependent insulin release. | Improved glycemic control and body weight reductions. Renoprotective actions | Reduction in levels of inflammatory markers including CRP, TNFα, IL6, and IL18. | (91–97)    |
| Pentoxifylline            | Inhibition of phosphodiesterases.                   | Reduced progression of renal disease and proteinuria.                                | Downregulation of NF-κB signaling and reduction of inflammatory biomarkers.              | (98–114)   |

DKD including increased vascular endothelium permeability (46), mesangial expansion and fibronectin expression (47), thickening of the glomerular basement membrane (48, 49), and renal hypertrophy (50). High serum and urine levels of the IL18 in type 2 diabetes have been proposed as early predictors of renal dysfunction, being related with the appearing of macroalbuminuria (18) and with the triggering of MAPK pathways by TGF-β (24). High serum TNFα levels have been clearly related with the pathophysiology of DKD including the development of renal hypertrophy and hyperfiltration (33). Levels of sodium retention, which is present in the early stages of DKD, has been related with urinary TNFα (51). Sodium retention in turn induce the expression of TGFβ and the development of renal hypertrophy (52). Moreover, the rise in both urinary and kidney-expressed TNFα levels precede the rise in albuminuria (53). These harmful effects elicited by TNFα in the kidney are mediated by the cytotoxicity on glomerular, mesangial, and epithelial cells (54–57). TNFα also change the permeability of endothelial cells, altering the equilibrium between vasoconstriction and vasodilation and the intraglomerular blood flow, which reduces glomerular filtration rate (GFR) independently from alterations in hemodynamic factors (58, 59). Moreover, TNFα also increases ROS levels in kidney cells independently of hemodynamic mechanisms,
altering the glomerular capillary wall and, consequently, increasing UAE (51, 59, 60).

IL17A exerts mainly proinflammatory responses via the activation of the NF-κB pathway and downstream regulation of proinflammatory genes (61). In podocytes in vitro, IL17A increased the expression of IL 6 and TNFα, particularly under conditions of high glucose concentration (62). Similarly, cultured tubular epithelial cells stimulated with this cytokine also present up-regulation of proinflammatory gene expression and monocyte chemoattractant protein 1 (MCP1) production (62, 63). Importantly, IL17A also induced epithelial-to-mesenchymal transition in cultured proximal tubular epithelial cells (64), indicating that this could be another mechanism of renal damage triggered by this cytokine. In experimental models, administration of IL17A in mice significantly upregulated kidney Mcp-1 and Rantes gene expression and the recruitment of inflammatory cells to the kidney (65). In leptin deficient BTBR ob/ob mice, the administration of a neutralizing anti-IL17A antibody resulted in an inhibition of NF-κB activation (66). Similarly, neutralization of IL17A also decreased proinflammatory genes and inflammatory cell infiltration in an experimental angiotensin II-induced renal damage model (67). Taken together, these observations suggest that local IL17A production in diabetic kidneys could activate resident renal cells to produce proinflammatory cytokines and chemokines, such as MCP-1, thereby amplifying the inflammatory response. Although many studies have addressed circulating or urinary IL17A levels in DN patients, the determination of local renal levels of IL17A has not been investigated yet.

INFLAMMATION AS A THERAPEUTIC TARGET IN DKD

Up to the present time, the main therapeutic strategy to slow the development and progression of DKD focus on the tight regulation of glucose levels and blood pressure by the utilization of RAS blockers: angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs). Although this therapeutic approximation reduces the risk of nephropathy progression, they do not completely halt the evolution toward end-stage renal disease (ESRD), with a still significant residual renal risk.

The important role played by inflammation, and specifically the involvement of inflammatory cytokines in the pathophysiology of ERD, constitute a new therapeutic opportunity in DKD to improve kidney function by the pharmacological reduction of the levels of these molecules (Table 1). Interestingly, the reduction in proteinuria and the slowdown in the progression of diabetic and non-diabetic nephropathies derived from RAS blockade has been related not only to hemodynamic/antihypertensive but also to anti-inflammatory/antifibrotic effects. This anti-inflammatory effect is mediated by the inhibition of NF-κB dependent pathways (68), which include the production of the pro-inflammatory cytokines IL6 and TNFα (69).

In recent years, new antidiabetic drugs have emerged (Table 1). These drugs include SGLT2i (sodium-glucose cotransporter type 2 inhibitors), GLP-1RA (glucagon-like peptide-1 receptor agonist), and DPP-4i (dipeptidyl peptidase-4 inhibitors). These compounds improve albuminuria and other traits of DKD in diabetic patients but also have been demonstrated to exert anti-inflammatory effects with potential benefits in the delay of the progression of DKD. The group of SGLT2i (canagliflozin, dapagliflozin, and empagliflozin, among others) are very effective hypoglycemic agents that, beyond glycemic control, have shown potent cardiovascular and renal protective effects in the diabetic patient (70–72). The underlying mechanisms of these effects are not fully understood, but recent findings suggest that are related with the modulation of inflammatory cytokines at renal and systemic levels. A few small clinical pilot studies have shown reductions of inflammatory markers in type 2 diabetes patients treated with SGLT2i. In this sense, mildly reductions in serum concentrations of C-reactive protein (CRP), TNFα, IL6, IL1β, and IFN-γ were observed in diabetic patients treated with canagliflozin, dapagliflozin, and empagliflozin (74–80). While robust data on short and mainly long-term effects of SGLT2i are obtained from clinical studies with a larger number of patients, most of what is known about the anti-inflammatory actions of these drugs comes from experimental approximations, which have made possible to delve into the underlying mechanisms of this beneficial immunomodulatory effect. In HK2 cells, a line of human kidney proximal tubule cells, empagliflozin attenuated the expression of Toll-like receptor-4 (TLR4) induced by high glucose, NF-κB and activator protein1 (AP1) transcription factors binding to nuclear DNA, and secretion of collagen IV and IL6 (81). In vascular endothelial cells, canagliflozin inhibited IL1β-stimulated IL6 and MCP1 secretion by AMP-activated protein kinase dependent and independent mechanisms (82). In obese diabetic or prediabetic animals, SGLT2i reduces albuminuria and tubulointerstitial injury (83–85). Thereby, the slowing in the progression of renal complications in prediabetic rats treated with dapagliflozin was related with the suppression of renal inflammation (84). The expression of TNFα, IL1β, and IL6, as well as the infiltration of cells into atheromatous plaques, were reduced in the atherosclerosis mice model ApoE−/− after treatment with empagliflozin (86). Empagliflozin achieved significant reductions in albuminuria in animal models with type 1 diabetes that were related with lower levels of renal NFκB, MCP1, and IL6 (87). The inhibition of SGLT2 in experimental type 2 diabetes models, reduced glomerular macrophage infiltration and sclerosis (88) and attenuated the overexpression of NOX4, TGFβ, osteopontin, and MCP1 in the tubular cells induced by high glucose (89).

Several clinical trials suggest that the anti-diabetic drugs DPP-4i and GLP-1RA also possess beneficial renal effects (90, 91), potentially modulating the inflammatory response. The DPP-4i vildagliptin and sitagliptin reduced the levels of markers of inflammation in diabetic patients (92). Administration of GLP-1RA, exenatide or dulaglutide, reduced the levels of CRP in diabetic patients (93). Different clinical trials are presently
evaluating the effects of these anti-diabetic therapeutic agents on systemic and renal inflammation: GLP-1RA (exenatide or liraglutide) vs. a DPP-4i (NCT02150707) and liraglutide (LIRALBU; NCT02545738 and NCT01847313). In the meantime, the renoprotective effects derived from the treatment with GLP-1RA and DPP-4i have been demonstrated in the experimental setting employing animal models with kidney disease. The DPP-4i linagliptin reduced albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis, independently of the glycemic control, in a mouse model of DKD (94). Sitagliptin and linagliptin also suppressed the activity of NLRP3/inflammasome in an experimental model of nephropathy (95). The model of type 2 diabetes db/db mice reduced albuminuria levels and mesangial expansion after treatment with the GLP-1RA exenatide (96). This treatment also reduced the levels of inflammatory cytokines and adhesion molecules in type 1 in diabetic rats (97).

The utilization of microRNAs (miRNAs) to regulate Th17 cell differentiation by targeting transcription factors like orphan receptor yt (RORyt) and the activation of STAT-3 or key cytokines involved in this process have been tested in different models of autoimmune disease (115–118). In the context of kidney disease, a recent study described that miRNA-155 deficiency promoted nephrin acetylation and decreased renal damage in a hyperglycemia-induced nephropathy model; importantly these effects were associated with a reduction in IL17A production through the up-regulation of the suppressor of cytokine signaling 1 (SOCS1) expression (119). Similarly, miR-155 knockout mice presented a significant reduction of the Th17 immune response, less severe nephritis, and reduced histologic and functional injury in an experimental model of nephritis (120).

Another potential therapeutic opportunity is the administration of neutralizing antibodies against IL17A for the treatment of chronic human inflammatory diseases is being tested in several ongoing clinical trials (121, 122). Anti-IL17A biological agents like secukinumab, ixekizumab, and brodalumab were more effective than diverse anti-TNF alpha agents such as infliximab, adalimumab, and etanercept, but less so than certolizumab. Unfortunately, although it seems clear that IL17A could play an important role in the inflammatory component of kidney disease, there are no clinical trials focused on the effects of anti-IL17A antibodies on renal inflammatory diseases like DKD or even lupus nephritis (123).

Pentoxifylline (PTX) is a methyl-xanthine clinically used for the treatment of intermittent claudication with anti-inflammatory properties. Both experimental and clinical studies in diabetic patients support the renal protective action of PTX, evidenced by a decrease in proteinuria and, in some cases, an improvement in GFR (98–101, 108). It is important to note that this anti-proteinuric capacity is related to an anti-inflammatory effect (102–107), being associated with significant reductions in TNFα levels (108, 109). Similarly, CKD patients report a reduction in TNFα, fibrinogen, and CRP levels and a stabilization in kidney function after PTX treatment (110). In these same patients, 1-year treatment of PTX in addition to the ARB background therapy resulted in a reduction in proteinuria and urinary levels of TNFα and MCP1 (111). In the PREDIAN trial, DKD patients under RAS blockade and treated with PTX also presented a stabilization in the progression of kidney disease after 2 years of follow-up (112). Importantly, this outcome was accompanied by reductions in proteinuria and urinary TNFα levels. Two recent meta-analysis in patients with DKD indicate, on the one hand, that the anti-proteinuric effect of PTX in these patients is due to a lower production of pro-inflammatory cytokines (113) and, on the other hand, that PTX additively reduces both proteinuria and TNFα levels in patients treated with RAS inhibitors (114).

**DISCUSSION**

The dramatic increase in the incidence of diabetes has prompted new therapeutic strategies to treat DKD. Inflammation has revealed as a key factor in the development and progression of this complication, allowing the development of therapeutic approaches focused on the modulation of inflammatory processes. However, at the present time, clinical experience on the inhibition of inflammatory molecules and pathways in diabetic patients is scarce and more clinical trials are needed to examine their potential renoprotective efficacy.

**AUTHOR CONTRIBUTIONS**

JN-G, JD-C, and CF conceived the idea, prepared the final version, and finalized the manuscript. CF searched the literature, prepared the first and last part of the draft, and reviewed and approved the revised version. FS-Q prepared the third part of the draft. AP-C, AG-L, EM-N, and CM-F reviewed the literature, critically reviewed the final version, and approved the final manuscript. All authors have substantially contributed to the preparation of the manuscript and agree with the study.

**FUNDING**

This work was supported by PI07/0870, PI15/00298, PI16/02057, PI16/00024, ISCIII-RETIC REDinREN RD16/0009, Sociedad Española de Nefrología (S.E.N.) and ACINEF. We acknowledge cofunding by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea (Una forma de hacer Europa). JD-C was recipient of a contract from Miguel Servet Programme (CP20/00122) of the Instituto de Salud Carlos III (ISCIII), CF was a recipient of a research contract from the ACIIISI (Agencia Canaria de Investigación, Innovación y Sociedad de la Información-TESI2018010110). EM-N was recipient of a research contract RD16/0009/0022 from REDinREN.
phospholipase A2 release from rat renal mesangial cells. *Biochem Biophys Res Commun.* (1989) 159:385–94. doi: 10.1016/0006-291X(89)90003-X

38. Pfeilschifter J, Mühl H. Interleukin 1 and tumor necrosis factor potentiate angiogenesis in cultured mesangial cells. *Biochem Biophys Res Commun.* (1990) 169:585–93. doi: 10.1016/S0006-291X(90)90371-S

39. Jones S, Jones S, Phillips AO. Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. *Kidney Int.* (2001) 59:1739–49. doi: 10.1121/1.559001739.x

40. Mahadevan P, Larkins RG, Fraser JR, Fosang AJ, Dunlop ME. Increased angiotensin II- and calcium ionophore-stimulated prostaglandin E2 phospholipase A2 release from rat renal mesangial cells. *Diabetologia.* (1995) 38:298–305. doi: 10.1007/BF00406634

41. Vasanthakumar R, Mohan V, Anand G, Deepa M, Babu S, Aravindhan V. Serum IL-9, IL-17, and TGF-beta levels in subjects with diabetic kidney disease (CURES-134). *Cytokine.* (2015) 72:109–12. doi: 10.1016/j.cyto.2014.10.009

42. Mohamed R, Jayakumar C, Chen F, Fulton D, Stepp D, Gansevoort RT, et al. Low-dose IL-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis. *J Am Soc Nephrol.* (2016) 27:745–65. doi: 10.1681/ASN.2014111136

43. Zhang N, Tai J, Qu Z, Zhang Z, Zhao S, He J, et al. Increased CD4^+ CXCR5^+ T follicular helper cells in diabetic nephropathy. *Autoimmunity.* (2016) 49:405–13. doi: 10.1080/08966566.2016.1196674

44. Galvan DL, Danesh FR. Paradoxical role of IL-17 in progression of diabetic nephropathy. *J Am Soc Nephrol.* (2016) 27:657–8. doi: 10.1681/ASNA2015070813

45. Liu Y. Cellular and molecular mechanisms of renal fibrosis. *Nat Rev Nephrol.* (2011) 7:684–96. doi: 10.1038/nrneph.2011.149

46. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Araki S, Haneda M, Koya D, Sugimoto T, Isshiki K, Chin-Kanaka M, et al. Interleukin-17A blockade reduces albuminuria and kidney injury in a rodent model of diabetic nephropathy. *Kidney Int.* (2012) 82. doi: 10.1681/ASN.2004110961

47. Araki S, Haneda M, Koya D, Sugimoto T, Ishikii K, Chin-Kanaka M, et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. *Diabetologia.* (2007) 50:867–73. doi: 10.1007/s00125-006-0586-8

48. DiPetrillo K, Coutermarch B, Gesek FA. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. *Am J Physiol Renal Physiol.* (2003) 284:F113–21. doi: 10.1152/ajprenal.00002.6.2002

49. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. *Circulation.* (1998) 98:2361–8. doi: 10.1161/01.CIR.98.23.2361

50. Kalandarina K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. *Kidney Int.* (2003) 64:1208–13. doi: 10.1016/S1524-153X.2003.00237.x

51. Ortiz A, Bustos C, Alonso J, Alcázar R, López-Armada MJ, Plaza JJ, et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. *Adv Nephrol Necker Hosp.* (1995) 24:53–77.

52. Pfeilschifter J, Mühl H. Interleukin 1 and tumor necrosis factor potentiate angiogenesis in cultured mesangial cells. *Biochem Biophys Res Commun.* (1989) 159:385–94. doi: 10.1016/0006-291X(89)90003-X

53. Luster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. *J Immunol.* (1988) 141:2629–34.

54. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Araki S, Haneda M, Koya D, Sugimoto T, Isshiki K, Chin-Kanaka M, et al. Interleukin-17A blockade reduces albuminuria and kidney injury in a rodent model of diabetic nephropathy. *Kidney Int.* (2012) 82. doi: 10.1681/ASN.2004110961

55. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaría B, Ruiz-Ortega M, et al. NF-kappaB inhibition decreases macrophage infiltration in experimental diabetic nephropathy. *Am J Pathol.* (2011) 179:1023–33. doi: 10.1016/j.ajpath.2010.08.006

56. Kalandarina K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. *Kidney Int.* (2003) 64:1208–13. doi: 10.1016/S1524-153X.2003.00237.x

57. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. *Arterioscler Thromb Vasc Biol.* (2003) 23:1553–8. doi: 10.1161/01.ATV.0000084961.44581.B7

58. Baud L, Perez J, Friedlander G, Ardaillou R. Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. *Fibers Lett.* (1998) 239:50–4. doi: 10.1016/S1898-8054(3).32872-2

59. McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XJ, Dileepan KN, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. *J Am Soc Nephrol.* (2003) 19:943–3.

60. Koike N, Takamura T, Kaneko S. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor. *Life Sci.* (2007) 80:1721–8. doi: 10.1016/j.lfs.2007.02.001

61. Cortivriz C, Speeckaert R, Moerman A, Delanghe JR, Speeckaert MM. The role of interleukin-17A in the pathogenesis of kidney disease. *Pathology.* (2017) 49:247–58. doi: 10.1016/j.pathol.2017.01.003

62. Ma J, Li YJ, Chen X, Kwan T, Chadbain SI, Wu H. Interleukin 17A promotes diabetic kidney injury. *Sci Rep.* (2019) 9:2264. doi: 10.1038/s41598-019-38811-4

63. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaría B, Ruiz-Ortega M, et al. NF-kappaB inhibition decreases macrophage infiltration in experimental diabetic nephropathy. *Am J Pathol.* (2011) 179:1023–33. doi: 10.1016/j.ajpath.2010.08.006

64. Kalandarina K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. *Kidney Int.* (2003) 64:1208–13. doi: 10.1016/S1524-153X.2003.00237.x

65. Ortiz A, Bustos C, Alonso J, Alcázar R, López-Armada MJ, Plaza JJ, et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. *Adv Nephrol Necker Hosp.* (1995) 24:53–77.

66. Pfeilschifter J, Mühl H. Interleukin 1 and tumor necrosis factor potentiate angiogenesis in cultured mesangial cells. *Biochem Biophys Res Commun.* (1989) 159:385–94. doi: 10.1016/0006-291X(89)90003-X

67. Luster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. *J Immunol.* (1988) 141:2629–34.
by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care.* (2010) 33:2217–24. doi: 10.2337/dc10-0612

76. Okamoto A, Yokokawa H, Sanada H, Naito T. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. *Drugs R D.* (2016) 16:255–61. doi: 10.1007/s40268-016-0137-9

77. Hattori S. Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance. *J Diabetes Investig.* (2018) 9:870–4. doi: 10.1111/jdi.12781

78. Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of Dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. *Curr Ther Res Clin Exp.* (2017) 87:13–9. doi: 10.1016/j.jcurthe.2017.07.002

79. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetes mellitus with chronic heart failure. *Cardiovasc Diabetol.* (2018) 17:132. doi: 10.1186/s12933-018-0775-x

80. Kim SR, Lee SG, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibitor, slows the progression of renal complications through the activation of advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. *Diabetes Metab Res Rev.* (2013) 29:624–8. doi: 10.1002/dmrr.1227

81. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy? *PLoS ONE.* (2013) 8:e54442. doi: 10.1371/journal.pone.0054442

82. Mancini SJ, Boyd D, Katwan OI, Strembtska A, Almabrouk TA, Kennedy S, et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. *Sci Rep.* (2018) 8:5276. doi: 10.1038/s41598-018-23420-4

83. Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. *Horm Metab Res.* (2016) 48:191–5. doi: 10.1055/s-0035-1555791

84. Iaikumkao K, Pongchaidecha A, Chueakula N, Thongnak LO, Wanchai K, Chatsudhipong V, et al. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. *Diabetes Obes Metab.* (2018) 20:2617–26. doi: 10.1111/dobm.13441

85. Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KK/ Ay/Ta mice, obese and type 2 diabetic animals. *Diab Vasc Dis Res.* (2013) 16:438–41. doi: 10.1177/14791641146657304

86. Han JH, Oh TJ, Lee G, Thongnak LO, Wanchai K, Chatsudhipong V, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE−/− mice fed a western diet. *Diabetologia.* (2017) 60:364–76. doi: 10.1007/s00125-016-4158-2

87. Vallon V, Gerasimova M, Rose MA, Masuda T, Miyamoto S, Satriano J, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. *Cardiovasc Diabetol.* (2014) 13:148. doi: 10.1186/12933-014-0148-1

88. Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. *PLoS ONE.* (2014) 9:e100777. doi: 10.1371/journal.pone.0100777

89. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. *Endocr J.* (2011) 58:69–73. doi: 10.1507/endocrj.K10E-382
109. Rodríguez-Morán M, González-González G, Bermúdez-Barba MV, Medina de la Garza CE, Tamez-Pérez HE, Martínez-Martínez FJ, et al. Effects of pentoxifylline on the urinary protein excretion profile in type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. *Clin Nephrol.* (2006) 66:63–10. doi: 10.5414/CNP66003

110. Goicoechea M, García de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. *Clin Nephrol.* (2006) 66:3–10. doi: 10.5414/CNP66003

111. Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. *Am J Kidney Dis.* (2008) 52:464–74. doi: 10.1053/j.ajkd.2008.05.012

112. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Chahin J, Méndez ML, Gallego E, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. *J Am Soc Nephrol.* (2015) 26:220–9. doi: 10.1681/ASN.2014010012

113. McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. *Am J Kidney Dis.* (2008) 52:454–63. doi: 10.1053/j.ajkd.2008.01.025

114. Tian ML, Shen Y, Sun ZL, Zha Y. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. *Int Urol Nephrol.* (2015) 47:815–22. doi: 10.1007/s11255-015-0968-2

115. Zhu E, Wang X, Zheng B, Wang Q, Hao J, Chen S, et al. miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORγt and STAT3. *J. Immunol.* (2014) 192:5399–609. doi: 10.4049/jimmunol.1303488

116. Qu X, Zhou J, Wang T, Han J, Ma L, Yu H, et al. MiR-30a inhibits Th17 differentiation and demyelination of EAE mice by targeting the IL-21R. *Brain Behav Immun.* (2016) 57:193–9. doi: 10.1016/j.bbi.2016.03.016

117. Li B, Wang X, Choi JY, Wang YC, Liu S, Pham AT, et al. MiR-146a modulates autoreactive Th17 cell differentiation and regulates organ-specific autoimmunity. *J Clin Investig.* (2017) 127:3702–16. doi: 10.1172/JCI94012

118. Naghavian R, Ghaedi K, Kiani-Esfahani A, Ganjalikhanian-Hakemi M, Etemadifar M, Nasr-Esfahani MH. miR-141 and miR-200a, revelation of new possible players in modulation of Th17/treg differentiation and pathogenesis of multiple sclerosis. *PLoS ONE.* (2015) 10:e0124555. doi: 10.1371/journal.pone.0124555

119. Lin X, You Y, Wang J, Qin Y, Huang P, Yang F. MicroRNA-155 deficiency promotes nephrin acetylation and attenuates renal damage in hyperglycemia-induced nephropathy. *Inflammation.* (2015) 38:546–54. doi: 10.1007/s10753-014-9961-7

120. Krebs CF, Kapffer S, Pautz HJ, Schmidt T, Bennstein SB, Peters A, et al. MicroRNA-155 drives TH17 immune response and tissue injury in experimental crescentic GN. *J Am Soc Nephrol.* (2013) 24:1955–65. doi: 10.1681/ASN.2013020130

121. Mease P, Van der Heijde D, Landewe R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis.* (2018) 77:890–9. doi: 10.1136/annrheumdis-2017-212687

122. Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst Rev.* (2017) 12:CD011353. doi: 10.1002/14651858.CD011353.pub2

123. Lavoz C, Rayego-Mateos S, Orejudo M, Opazo-Ríos L, Marchant V, Marquez-Exposito L, et al. Could IL-17A be a novel therapeutic target in diabetic nephropathy? *J Clin Med.* (2020) 9:272. doi: 10.3390/jcm9010272

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Donate-Correa, Ferri, Sánchez-Quintana, Pérez-Castro, González-Luis, Martín-Núñez, Mora-Fernández and Navarro-González. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*